Test Your Knowledge

Quiz: Does Dalpiciclib Plus Pryrotinib Yield Promise as Chemo-Free Alternative for HER2+BC?

11/17/2021

Recent News

FDA Approval

FDA Approves Zenocutuzumab for Patients With NRG1 Fusion-Positive Advanced Cholangiocarcinoma

05/08/2026

Stephanie Holland

Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.

Based on results from the phase...

05/08/2026

Oncology

News

Daraxonrasib Shows Clinical Promise in Patients With RAS-mutated Pancreatic Ductal Adenocarcinoma

05/07/2026

Stephanie Holland

Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.

Results from a phase 1/2 study...

05/07/2026

Oncology

FDA Approval

FDA Approves Extended-Release Ruxolitinib Across Hematologic Indications

05/07/2026

Stephanie Holland

Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.

Based on pharmacokinetic...

05/07/2026

Oncology

FDA Alerts

Camizestrant Fails to Gain Support from the FDA’s Advisory Committee in ESR1-Mutated Advanced Breast Cancer

05/07/2026

Stephanie Holland

Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...

Based on results from the...

05/07/2026

Oncology

News

Complete Consolidative Radiotherapy Improves Survival in Extensive-Stage Small Cell Lung Cancer

05/07/2026

Emily Estrada

Results from a retrospective cohort study demonstrated that completion of consolidative radiotherapy was associated with significantly improved survival outcomes in patients with extensive-stage small cell lung cancer.

Results from a retrospective...

05/07/2026

Oncology

News

Oligoprogression Predicts Improved Survival After Chemoimmunotherapy in Relapsed Small Cell Lung Cancer

05/07/2026

Emily Estrada

Results from a retrospective analysis demonstrated that patterns of post-chemoimmunotherapy progression were strongly associated with outcomes in relapsed small cell lung cancer.

Results from a retrospective...

05/07/2026

Oncology

News

Giredestrant Demonstrates Antiproliferative Activity in Premenopausal Patients With Early Breast Cancer

05/07/2026

Stephanie Holland

Results from the phase 2 PREcoopERA trial demonstrated that giredestrant shows antiproliferative activity in premenopausal ER-positive, HER2-negative early breast cancer.

Results from the phase 2...

05/07/2026

Oncology

News

Glecirasib-Based Regimens Show Promise in KRAS G12C-Mutant Metastatic Colorectal Cancer

05/07/2026

Emily Estrada

Combined results from the JAB-21822-1002 and JAB-21822-1007 trials demonstrate that glecirasib shows clinical promise both alone and in combination with cetuximab in KRAS G12C-mutated locally advanced or metastatic colorectal cancer.

Combined results from the...

05/07/2026

Oncology

News

ctDNA Dynamics to Predict Survival Outcomes in Patients With Metastatic Colorectal Cancer

05/07/2026

Emily Estrada

Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.

Exploratory ctDNA results from...

05/07/2026

Oncology

FDA Alerts

Capivasertib Gains Support from the FDA’s Advisory Committee in Metastatic Hormone-Sensitive Prostate Cancer

05/04/2026

Stephanie Holland

Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...

Based on results from the phase...

05/04/2026

Oncology